Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California. more
Time Frame | CLDI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -22.46% | -3.35% | -2.97% |
1-Month Return | -39.58% | -3.49% | -0.66% |
3-Month Return | 31.22% | -12.6% | 2.71% |
6-Month Return | -25.64% | -6.91% | 7.21% |
1-Year Return | -91.94% | 1.19% | 23.04% |
3-Year Return | 144900% | -0.21% | 28.43% |
5-Year Return | 144900% | 33.09% | 82.88% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | 449.00K | 45.00K | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":10.02,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | - | 94.00K | 274.00K | 1.26M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":7.48,"profit":true},{"date":"2022-12-31","value":21.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | - | 355.00K | (229.00K) | (1.26M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-64.51,"profit":false},{"date":"2023-12-31","value":-353.8,"profit":false}] | |
Gross Margin | - | 79.06% | (508.89%) | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-643.64,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 6.77M | 1.78M | 22.90M | 28.99M | [{"date":"2020-12-31","value":23.36,"profit":true},{"date":"2021-12-31","value":6.15,"profit":true},{"date":"2022-12-31","value":78.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (6.77M) | (1.78M) | (23.13M) | (28.99M) | [{"date":"2020-12-31","value":-677300000,"profit":false},{"date":"2021-12-31","value":-178170000,"profit":false},{"date":"2022-12-31","value":-2312800000,"profit":false},{"date":"2023-12-31","value":-2899200000,"profit":false}] | |
Total Non-Operating Income/Expense | (1.32M) | (1.05M) | (2.41M) | (3.96M) | [{"date":"2020-12-31","value":-132300000,"profit":false},{"date":"2021-12-31","value":-105400000,"profit":false},{"date":"2022-12-31","value":-241000000,"profit":false},{"date":"2023-12-31","value":-395700000,"profit":false}] | |
Pre-Tax Income | (7.93M) | 3.39M | (25.42M) | (29.20M) | [{"date":"2020-12-31","value":-234.24,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-750.45,"profit":false},{"date":"2023-12-31","value":-862.18,"profit":false}] | |
Income Taxes | 4.00K | 11.00K | 11.00K | 16.00K | [{"date":"2020-12-31","value":25,"profit":true},{"date":"2021-12-31","value":68.75,"profit":true},{"date":"2022-12-31","value":68.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Income After Taxes | (7.94M) | 3.38M | (25.43M) | (29.22M) | [{"date":"2020-12-31","value":-235.12,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-753.23,"profit":false},{"date":"2023-12-31","value":-865.47,"profit":false}] | |
Income From Continuous Operations | (7.94M) | (10.93M) | (21.16M) | (29.22M) | [{"date":"2020-12-31","value":-793700000,"profit":false},{"date":"2021-12-31","value":-1093300000,"profit":false},{"date":"2022-12-31","value":-2116000000,"profit":false},{"date":"2023-12-31","value":-2921600000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (7.94M) | 3.39M | (25.43M) | (29.22M) | [{"date":"2020-12-31","value":-234.35,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-750.78,"profit":false},{"date":"2023-12-31","value":-862.66,"profit":false}] | |
EPS (Diluted) | - | 0.12 | (0.05) | (3.30) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-41.67,"profit":false},{"date":"2023-12-31","value":-2753.42,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
CLDI | |
---|---|
Cash Ratio | 0.16 |
Current Ratio | 0.19 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CLDI | |
---|---|
ROA (LTM) | -222.49% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CLDI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 2.47 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.54 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CLDI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 50.83 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 49.42 |
EV/Ebitda | NM |
Calidi Biotherapeutics Inc. (CLDI) share price today is $1.45
Yes, Indians can buy shares of Calidi Biotherapeutics Inc. (CLDI) on Vested. To buy Calidi Biotherapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CLDI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Calidi Biotherapeutics Inc. (CLDI) via the Vested app. You can start investing in Calidi Biotherapeutics Inc. (CLDI) with a minimum investment of $1.
You can invest in shares of Calidi Biotherapeutics Inc. (CLDI) via Vested in three simple steps:
The 52-week high price of Calidi Biotherapeutics Inc. (CLDI) is $16.9. The 52-week low price of Calidi Biotherapeutics Inc. (CLDI) is $0.73.
The price-to-earnings (P/E) ratio of Calidi Biotherapeutics Inc. (CLDI) is
The price-to-book (P/B) ratio of Calidi Biotherapeutics Inc. (CLDI) is 0.00
The dividend yield of Calidi Biotherapeutics Inc. (CLDI) is 0.00%
The market capitalization of Calidi Biotherapeutics Inc. (CLDI) is $24.64M
The stock symbol (or ticker) of Calidi Biotherapeutics Inc. is CLDI